Skip to main content
Premium Trial:

Request an Annual Quote

NIH Launches Web Service to Connect Inventors With Commercial Partners

NEW YORK (GenomeWeb News) — The National Institutes of Health has started a web-based program designed to connect NIH licensees and grant awardees to potential commercialization partners, the NIH said Wednesday.
 
The NIH Pipeline to Partnerships initiative, known as P2P, is designed to enable licensees and awardees, especially early-stage developers, to “showcase their technologies and product development for an audience of potential strategic partners, investors, and licensees,” NIH said.
 
"In the last decade, many successful biomedical products have come from pharmaceutical and biotechnology companies that licensed early-stage technologies from NIH," said Mark Rohrbaugh, director of the NIH’s Office of Technology Transfer, which helped develop the initiative with the NIH Small Business Innovation Research and Small Business Technology Transfer programs.
 
"Faced with less demand for early-stage technologies, this pipeline provides an avenue for potential partners to find NIH licensees along the spectrum of product development to share costs, infrastructure, and expertise as the research and development progresses to later stage clinical trials," he added.
 
The NIH said researchers can view the pipeline of technologies, searchable by category and stage, on OTT’s website.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.